• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tumor Treating Fields (TTF) with Triple Chemotherapy for Recurrent Glioblastoma (P1.177)
Conclusions:Therapies with TTF plus TBC demonstrates superior OS benefit for recurrent GBM with moderate, but manageable side effects. A prospective study of TTF plus TBC for recurrent GBM is warranted.Study Supported by: Dr. Marnie Rose FoundationDisclosure: Dr. Zhu has received personal compensation for activities with Novocure, and Prime Oncology. Dr. Zhu has received research support from Novocure, Inc., Five Prime Therapeutics, Immuno-Cellular Inc., DEKK-TEC. Dr. Lu has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Zhu has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Zhu, J.-J., Lu, G., Rao, M., Zhu, P. Tags: Neuro-oncology: Gliomas I Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research